Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance

NCT02606266 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped No eligibles patients

Conditions

Congenital Cytomegalovirus (CMV)

Interventions

DRUG: Valganciclovir

Sponsor

Assistance Publique - Hôpitaux de Paris